The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dose-expansion part of a phase 1b global study of E7386 in combination with lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC) and other solid tumors including endometrial cancer (EC).
 
Jung-Yun Lee
Consulting or Advisory Role - AstraZeneca; MSD; Roche; Takeda
Research Funding - Ascendis Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (Inst); Immunogen (Inst); Janssen Oncology (Inst); Merck (Inst); Mersana (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); OncoQuest Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); Synthon (Inst); Takeda (Inst)
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
Jin Won Kim
Consulting or Advisory Role - AstraZeneca; BeiGene Beijing; BeiGene Beijing; BeyondBIO; Bristol-Myers Squibb/Celgene; Eisai; GC Cell; MSD; Ono Pharmaceutical; Roche; Sanofi; Servier; TCUBEit
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; BeiGene; Bristol-Myers Squibb; Eisai; Genentech/Roche; Ipsen; IQVIA; MSD; Omega Therapeutics, Inc.; Ono Pharmaceutical; Roche
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Hengrui Therapeutics; Lilly; Medivir; Medivir; Merck; Pfizer
Speakers' Bureau - Genentech
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Kosei Hasegawa
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Genmab; Kyowa Kirin; MSD K.K; Sanofi; Takeda
Consulting or Advisory Role - Daiichi Sankyo; Genmab; Kaken Pharmaceutical; MSD K.K; Roche; Sanofi; Takeda
Research Funding - Daiichi Sankyo; Merck; Ono Pharmaceutical
 
Vicky Makker
Consulting or Advisory Role - ArQule; Clovis Oncology; DualityBio; Eisai; Faeth Therapeutics; GlaxoSmithKline; IBM; ITeos Therapeutics; Kartos Therapeutics; Karyopharm Therapeutics; Lilly; Merck; Novartis; Takeda
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); DualityBio (Inst); Eisai (Inst); Faeth Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Eisai; ESMO Congress; Merck
Other Relationship - IBM
 
Masatoshi Kudo
Honoraria - AstraZeneca; Bayer; Chugai/Roche; Eisai; Lilly Japan; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai/Roche; Eisai; Roche
Research Funding - Abbvie (Inst); Chugai/Roche (Inst); Eisai (Inst); GE Healthcare (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
David Scott Miller
Consulting or Advisory Role - Abbvie; Agenus; AstraZeneca; Asymmetric Therapeutics; BOSTON BIOMEDICAL RESEARCH INSTITUTE; Clinical Education Alliance; Eisai; Eisai; EMD Serono; GlaxoSmithKline; GlaxoSmithKline; Immunogen; Incyte; Incyte; ITeos Therapeutics; Karyopharm Therapeutics; Merck Sharp & Dohme; Myriad Genetic Laboratories; Novartis; Novocure; Seagen; Tarveda Therapeutics
Research Funding - Advaxis (Inst); Advenchen Laboratories (Inst); Aeterna Zentaris (Inst); Agenus (Inst); Akeso Biopharma (Inst); Aprea AB (Inst); AstraZeneca (Inst); EMD Serono; Immunogen (Inst); Incyte (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics; Mateon Therapeutics (Inst); Merck Sharp & Dohme (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); NVision (Inst); Pfizer (Inst); Regeneron (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst); TRACON Pharma (Inst); US Biotest (Inst); Xenetic Biosciences (Inst)
 
Philippe Merle
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Ipsen; MSD; Roche
 
Susanna Varkey Ulahannan
Consulting or Advisory Role - AstraZeneca; Eisai; IgM Biosciences
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); ArQule (Inst); Artios (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); atreca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CicloMed (Inst); Eisai (Inst); Erasca, Inc (Inst); evelo biosciences (Inst); Exelixis (Inst); Exelixis (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); IgM Biosciences (Inst); immunitas (Inst); Incyte (Inst); Jazz Pharmaceuticals (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); NGM Biopharmaceuticals (Inst); Omega Therapeutics (Inst); OncoMed (Inst); Pfizer (Inst); Pionyr (Inst); Purple Biotech (Inst); Regeneron (Inst); Revolution Medicines (Inst); Synermore biologics (Inst); Takeda (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tempest Therapeutics (Inst); Tesaro (Inst); Theradex (Inst); Totus Medicines (Inst); Tvardi Therapeutics (Inst); Tvardi Therapeutics (Inst); Vigeo Therapeutics (Inst)
 
Tetsuya Hosaka
Speakers' Bureau - Eisai; Gilead Sciences
 
Takatoshi Sahara
Employment - Eisai
 
Cixin S. He
No Relationships to Disclose
 
Karen O'Hara
Employment - Eisai
 
Lea Dutta
Employment - Eisai
 
Toshiyuki Tamai
Employment - Eisai
 
Masafumi Ikeda
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Eisai; Fujifilm; Guardant Health; Incyte; Lilly Japan; MSD; Nihonkayaku; Nobelpharma; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Boston Scientific; Chugai Pharma; Eisai; Guardant Health; MSD; Novartis; Roche; SERVIER
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Nobelpharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Rakuten Medical Japan (Inst); Syneos Health (Inst)